EuroAPI EuroAPI

X
[{"orgOrder":0,"company":"Northway Biotechpharma","sponsor":"Memo Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Memo Therapeutics AG and Northway Biotechpharma Collaborate Fast-Track Manufacturing of a SARS-CoV-2-Neutralizing Antibody for COVID-19","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Discovery","country":"LITHUANIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Large molecule","graph2":"Northway Biotechpharma"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the terms of the agreement, Northway will develop the cell line and the manufacturing process, and will further produce cGMP batches of MTx´s antibody for clinical studies and will also execute commercial production once MTX-COVAB receives marketing authorization.

            Lead Product(s): MTX-COVAB

            Therapeutic Area: Infections and Infectious Diseases Product Name: MTX-COVAB

            Highest Development Status: Discovery Product Type: Large molecule

            Partner/Sponsor/Collaborator: Memo Therapeutics

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Partnership August 14, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY